The drugmaker plans to build a research-and-development center in Beijing and strike deals with local biotechnology companies ...

Berenberg Bank reaffirmed their buy rating on shares of AstraZeneca (LON:AZN – Free Report) in a research report sent to ...

For this article, we used a Finviz screener to filter all the available ADR stocks. Then we compare the list with our Q4 2024 ...

Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said on Monday, ...

Xponance Inc. raised its position in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 6.9% during the fourth quarter, ...

AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker ...

AstraZeneca plans to build a $2.5 billion research and development center in Beijing, the Britain-based multinational ...

Cambridge-headquartered AstraZeneca is investing $2.5 billion in Beijing to establish its sixth global strategic R & D centre ...

Multinational pharmaceutical company AstraZeneca is bullish about China's role as a global innovation powerhouse, underpinned ...

The deal includes the Belgian biotech’s in-vivo cell-therapy platform, which modifies immune cells within the patient’s body, ...

British-Swedish drug maker has gone from Beijing’s scrutiny to its praise, hailed as a sign of doing business in China.

The investments come amid an ongoing investment fraud probe into AstraZeneca’s former China head Leon Wang—and despite ...